Aether Industries Q2 FY27 consolidated: Revenue Rs 347.22 cr, PAT Rs 68.00 cr
Results$AETHER

Aether Industries Q2 FY27 consolidated: Revenue Rs 347.22 cr, PAT Rs 68.00 cr

For Q2 FY27, Aether Industries’ consolidated revenue from operations was Rs 347.22 cr and PAT Rs 68.00 cr, up from Rs 280.10 cr and Rs 53.96 cr a year earlier.

Aether Industries Ltd
Aether Industries LtdReviewed and published by · How we report
2 min read
aether industriesq2 fy27 resultsfinancial resultsspeciality chemicals
ShareWhatsAppXLinkedIn

Key takeaways

  • Revenue from operations Rs 347.22 cr vs Rs 280.10 cr in Q2 FY26.
  • Total income Rs 352.29 cr vs Rs 288.79 cr in Q2 FY26.
  • Total expenses Rs 263.78 cr vs Rs 211.84 cr in Q2 FY26.
  • PAT Rs 68.00 cr vs Rs 53.96 cr in Q2 FY26.
  • Basic EPS Rs 5.12 vs Rs 4.07 in the corresponding quarter last year.

Q2 FY27 · consolidated

MetricSep 2026Sep 2025Change
RevenueRs 347.22 crRs 280.10 cr+24.0%
PATRs 68.00 crRs 53.96 cr+26.0%

As reported in the filing. Figures are transcribed, not computed.

What the numbers show

  • Net margin was 19.58% of revenue, up 31 bps from 19.26%.

• Revenue from operations (consolidated, Q2 FY27): Rs 347.22 cr vs Rs 280.10 cr in Q2 FY26, as per the statement of financial results.

• Total income: Rs 352.29 cr vs Rs 288.79 cr in Q2 FY26.

• Total expenses: Rs 263.78 cr vs Rs 211.84 cr in Q2 FY26.

• Cost of materials consumed: Rs 266.91 cr vs Rs 161.37 cr in Q2 FY26.

• Changes in inventories of finished goods and work-in-progress: Rs (9.97) cr vs Rs (18.67) cr in Q2 FY26.

• Employee benefit expenses: Rs 19.77 cr vs Rs 14.14 cr in Q2 FY26.

• Finance cost: Rs 5.31 cr vs Rs 3.23 cr in Q2 FY26.

• Depreciation and amortisation expenses: Rs 21.69 cr vs Rs 16.52 cr in Q2 FY26.

• Other expenses: Rs 49.77 cr vs Rs 35.24 cr in Q2 FY26.

• Profit before tax (after exceptional items): Rs 88.52 cr vs Rs 74.27 cr in Q2 FY26.

• Profit for the period (PAT): Rs 68.00 cr vs Rs 53.96 cr in Q2 FY26.

• Earnings per share (basic): Rs 5.12 vs Rs 4.07 in Q2 FY26.

• Earnings per share (diluted): Rs 5.11 vs Rs 4.07 in Q2 FY26.

For the quarter ended 30.09.2026, Aether Industries reported higher consolidated revenue from operations and total income compared with the corresponding quarter ended 30.09.2025, according to the statement of unaudited consolidated financial results. Revenue from operations rose to Rs 347.22 cr from Rs 280.10 cr, while total income increased to Rs 352.29 cr from Rs 288.79 cr.

On the cost side, cost of materials consumed increased to Rs 266.91 cr from Rs 161.37 cr a year earlier. Changes in inventories of finished goods and work-in-progress stood at Rs (9.97) cr compared with Rs (18.67) cr in the same quarter last year. Employee benefit expenses were Rs 19.77 cr versus Rs 14.14 cr, and finance cost was Rs 5.31 cr versus Rs 3.23 cr. Depreciation and amortisation expenses rose to Rs 21.69 cr from Rs 16.52 cr, while other expenses increased to Rs 49.77 cr from Rs 35.24 cr.

Total expenses for the quarter were Rs 263.78 cr, compared with Rs 211.84 cr in the year-ago quarter. Profit before tax after exceptional items was Rs 88.52 cr versus Rs 74.27 cr in Q2 FY26. After total tax expenses of Rs 20.52 cr (vs Rs 20.31 cr a year earlier), profit for the period came in at Rs 68.00 cr, up from Rs 53.96 cr.

Basic earnings per share for the quarter were Rs 5.12, compared with Rs 4.07 in the corresponding quarter of the previous year, while diluted earnings per share were Rs 5.11 versus Rs 4.07, based on a paid-up equity share capital of Rs 132.73 cr in Q2 FY27 and Rs 132.59 cr in Q2 FY26.

Track Aether Industries Ltd

Cruxal reads every Aether Industries Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.

Get every filing that moves a stock

One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.

Cruxal publishes market coverage for information only. Nothing here is investment advice.